The effect of indapamide on development of myocardial hypertrophy and fibrosis in L-NAME-induced hypertension in rat

Physiological Research

Volumn 60, Issue 6, 2011, Pages 845-852

  Hlavackova L ^a   Vrankova S ^a   Janega, P ^a,b   Pechanova O ^b   Babal P ^a  

^a Faculty of Natural Sciences   (Slovakia)

^b INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

Captopril; Indapamide; LV hypertrophy; Myocardial fibrosis; Red wine polyphenols

Indexed keywords

EID: 84856500577     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: 10.33549/physiolres.932201     Document Type: Article

References (43)

1. Allon I, Vered M, Buchner A, Dayan D: Stromal differences in salivary gland tumors of a common histopathogenesis but with different biological behavior: a study with picrosirius red and polarizing microscopy. Acta Histochem 108: 259-264, 2006.
2. Altieri P, Brunelli C, Garibaldi S, Nicolino A, Ubaldi S, Spallarossa P, Olivotti L, Rossettin P, Barsotti A, Ghigliotti G: Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur J Clin Invest 33: 648-656, 2003.
3. Arnal JF, El Amrani Ai, Chatellier G, Ménard J, Michel JB: Cardiac weight in hypertension induced by nitric oxide synthase blockade. Hypertension 22: 380-387, 1993.
4. Arnal JF, Warin L, Michel JB: Determinants of aortic cycLCI guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. J Clin Invest 90: 647-652, 1992.
5. Bartunek J, Weinberg Eo, Tajima M, Rohrbach S, Katz Se, Douglas Ps, Lorell BH: Chronic N(G)-nitro-L-arginine methyl ester-induced hypertension: novel molecular adaptation to systoLCI load in absence of hypertrophy. Circulation 101: 423-429, 2000.
6. Bernátová I, Pechánová O, BabáL P, Kyselá S, Stvrtina S, Andriantsitohaina R: Wine polyphenols improve cardiovascular remodeling and vascular function in NO-deficient hypertension. Am J Physiol Heart Circ Physiol 282: H942-H948, 2002.
7. Bernátová I, Pechánová O, Pelouch V, Simko F: Regression of chronic L -NAME-treatment-induced left ventricular hypertrophy: effect of captopril. J Mol Cell Cardiol 32: 177-185, 2000.
8. Bernátová I, Pechánová O, Simko F: Captopril prevents NO-deficient hypertension and left ventricular hypertrophy without affecting nitric oxide synthase activity in rats. Physiol Res 45: 311-316, 1996.
9. Conrad CH, Brooks Ww, Hayes Ja, Sen S, Robinson Kg, Bing OH: Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat. Circulation 91: 161-170, 1995.
10. Contard F, Glukhova M, Marotte F, Narcisse G, Schatz C, Swynghedauw B, Guez D, Samuel Jl, Rappaport L: Diuretic effects on cardiac hypertrophy in the stroke prone spontaneously hypertensive rat. Cardiovasc Res 27: 429-434, 1993.
11. Diebolt M, Bucher B, Andriantsitohaina R: Wine polyphenols decrease blood pressure, improve NO vasodilatation, and induce gene expression. Hypertension 38: 159-165, 2001.
12. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ: Effect of singledrug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation 95: 2007-2014, 1997.
13. Hlavačková L, Janega P, Cerná A, Pecháňová O, Andriantsitohaina R, BabáL P: Red wine polyphenols affect the collagen composition in the aorta after oxidative damage induced by chronic administration of CCl4. Physiol Res 58: 337-344, 2009.
14. Innes BA, Mclaughlin MG, Kapuscinski MK, Jacob HJ, Harrap SB: Independent genetic susceptibility to cardiac hypertrophy in inherited hypertension. Hypertension 31: 741-746, 1998.
15. Janega P, Kojsová S, Jendeková L, Babál P, PecháNová O: Indapamide-induced prevention of myocardial fibrosis in spontaneous hypertension rats is not nitric oxide-related. Physiol Res 56: 825-828, 2007.
16. Kim YA, Lim SY, Rhee SH, Park KY, Kim CH, CHOI BT, LEE SJ, PARK YM, CHOI YH: Resveratrol inhibits inducible nitric oxide synthase and cyclooxygenase-2 expression in beta-amyloid-treated C6 glioma cells. Int J Mol Med 17: 1069-1075, 2006.
17. Kobayashi N, HAra K, Watanabe S, Higashi T, Matsuoka H: Effect of imidapril on myocardial remodeling in L-NAME-induced hypertensive rats is associated with gene expression of NOS and ACE mRNA. Am J Hypertens 13: 199-207, 2000.
18. Kojsová S, Jendeková L, Zicha J, Kunes J, Andriantsitohaina R, Pechánová O: The effect of different antioxidants on nitric oxide production in hypertensive rats. Physiol Res 55 (Suppl 1): S3-S16, 2006.
19. Leikert JF, Räthel TR, Wohlfart P, Cheynier V, Vollmar AM, Dirsch VM: Red wine polyphenols enhance endothelial nitric oxide synthase expression and subsequent nitric oxide release from endothelial cells. Circulation 106: 1614-1617, 2002.
20. Machová A: The diuretic effect of metipamide and its relationship to body weights in rats. Physiol Bohemoslov 37: 149-158, 1988.
21. Marijianowski MM, Teeling P, Mann J, Becker AE: Dilated cardiomyopathy is associated with an increase in the type I/type III collagen ratio: a quantitative assessment. J Am Coll Cardiol 25: 1263-1272, 1995.
22. Moreno H Jr, Metze K, Bento AC, Antunes E, Zatz R, De Nucci G: Chronic nitric oxide inhibition as a model of hypertensive heart muscle disease. Basic Res Cardiol 91: 248-255, 1996.
23. Mukherjee D, Sen S: Alteration of cardiac collagen phenotypes in hypertensive hypertrophy: role of blood pressure. J Mol Cell Cardiol 25: 185-196, 1993.
24. Mukherjee D, Sen S: Collagen phenotypes during development and regression of myocardial hypertrophy in spontaneously hypertensive rats. Circ Res 67: 1474-1480, 1990.
25. Narayan S, Janicki JS, Shroff SG, Pick R, Weber KT: Myocardial collagen and mechanics after preventing hypertrophy in hypertensive rats. Am J Hypertens 2: 675-682, 1989.
26. Nguyen T, El Salibi E, Rouleau JL: Reduced periinfarction mortality as a result of long-term therapy with captopril but not hydralazine or propranolol in spontaneously hypertensive rats. J Cardiovasc Pharmacol 32: 884-895, 1998.
27. Oak MH, El Bedoui J, Anglard P, Schini-Kerth VB: Red wine polyphenoLCI compounds strongly inhibit pro-matrix metalloproteinase-2 expression and its activation in response to thrombin via direct inhibition of membrane type 1-matrix metalloproteinase in vascular smooth muscle cells. Circulation 110: 1861-1867, 2004.
28. Pauschinger M, Knopf D, Petschauer S, Doerner A, Poller W, Schwimmbeck PL, Kühl U, Schultheiss HP: Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circulation 99: 2750-2756, 1999.
29. Pechánová O, Bernátová I, Babál P, Martínez MC, Kyselá S, Stvrtina S, Andriantsitohaina R: Red wine polyphenols prevent cardiovascular alterations in L-NAME-induced hypertension. J Hypertens 22: 1551-1559, 2004.
30. Pechánová O, Bernátová I, Pelouch V, Babál P: L-NAME-induced protein remodeling and fibrosis in the rat heart. Physiol Res 48: 353-362, 1999.
31. Pechánová O, Bernátová I, Pelouch V, Simko F: Protein remodelling of the heart in NO-deficient hypertension: the effect of captopril. J Mol Cell Cardiol 29: 3365-3374, 1997.
32. Serafini M, Maiani G, Ferro-Luzzi A: Alcohol-free red wine enhances plasma antioxidant capacity in humans. J Nutr 128: 1003-1007, 1998.
33. Schraeger JA, Canby CA, Rongish BJ, Kawai M, Tomanek RJ: Normal left ventricular diastoLCI compliance after regression of hypertrophy. J Cardiovasc Pharmacol 23: 349-357, 1994.
34. Simko F, Luptak I, Matuskova J, Krajcirovicova K, Sumbalova Z, Kucharska J, Gvozdjakova A, Simko J, Babal P, Pechanova O, Bernatova I: L-arginine fails to protect against myocardial remodelling in L-NAME-induced hypertension. Eur J Clin Invest 35: 362-368, 2005.
35. Takemoto M, Egashira K, Usui M, Numaguchi K, Tomita H, Tsutsui H, Shimokawa H, Sueishi K, Takeshita A: Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest 99: 278-287, 1997.
36. Varo N, Iraburu MJ, Varela M, López B, Etayo JC, Díez J: Chronic AT(1) blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension 35: 1197-1202, 2000.
37. Vergely C, Walker MK, Zeller M, Rademakers JR, Maupoil V, Schiavi P, Guez D, Rochette L: Antioxidant properties of indapamide, 5-OH indapamide and hydrochlorothiazide evaluated by oxygenradical absorbing capacity and electron paramagnetic resonance. Mol Cell Biochem 178: 151-155, 1998.
38. Vranková S, Jendekova L, Paulis L, Sladkova M, Simko F, Pechanova O: Comparison of the effects of indapamide and captopril on the development of spontaneous hypertension. J Hypertens Suppl 27: S42-S46, 2009.
39. Weber KT: Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 13: 1637-1652, 1989.
40. Wei S, Chow LT, Shum IO, Qin L, Sanderson JE: Left and right ventricular collagen type I/III ratios and remodeling post-myocardial infarction. J Card Fail 5: 117-126, 1999.
41. Weisinger RS, Stanley TK, Begg DP, Weisinger HS, Spark KJ, Jois M: Angiotensin converting enzyme inhibition lowers body weight and improves glucose tolerance in C57BL/6J mice maintained on a high fat diet. Physiol Behav 98: 192-197, 2009.
42. Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, Yoshida J, Miwa T, Sugawara M, Yamaguchi Y, Ookawara T, Suzuki K, Hori M: Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res 55: 76-82, 2002.
43. Zhang Y, Agnoletti D, Safar ME, Blacher J: Effect of antihypertensive agents on blood pressure variability: the Natrilix SR versus candesartan and amlodipine in the reduction of systolic blood pressure in hypertensive patients (X-CELLENT) study. Hypertension 58: 155-160, 2011.